Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Barr on the Rationale for the Long-Term Evaluation of the RESONATE-2 Trial in CLL

June 30th 2021

Paul M. Barr, MD, discusses the rationale for the long-term analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Ghia on the Rationale for the CAPTIVATE Trial in CLL

June 29th 2021

Paolo Ghia, MD, PhD, discusses the rationale for the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Ailawadhi on the Safety Profile of Lisaftoclax in CLL

June 25th 2021

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Dr. Abedin on Managing Cardiac Toxicities With Acalabrutinib vs Ibrutinib in CLL

June 22nd 2021

Sameem Abedin, MD, discusses managing cardiac toxicities with acalabrutinib vs ibrutinib in patients with chronic lymphocytic leukemia.

Dr. Abedin on Frontline Treatment Considerations in CLL 

June 21st 2021

Sameem Abedin, MD, discusses frontline treatment considerations for patients with chronic lymphocytic leukemia.

Pirtobrutinib Elicits Encouraging Efficacy in CLL, SLL, MCL, & Other Non-Hodgkin Lymphomas

June 21st 2021

Pirtobrutinib produced promising efficacy in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma, those with mantle cell lymphoma and other non-Hodgkin lymphomas, and those who progressed on Richter transformation–directed therapy.

Dr. Abedin on the Clinical Significance of Undetectable MRD in CLL

June 21st 2021

Sameem Abedin, MD, discusses the clinical significance of undetectable minimal residual disease status in chronic lymphocytic leukemia.

Dr. Siddiqi on the Role of Acalabrutinib in Frontline CLL

June 16th 2021

Tanya Siddiqi, MD, discusses the role of acalabrutinib as a frontline treatment for patients with chronic lymphocytic leukemia.

Dr. Byrd on the Clinical Implications of the ELEVATE-RR Trial in CLL

June 16th 2021

John C. Byrd, MD, discusses the clinical implications of the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

An Expert Provides Insight Into the Use of BTK Inhibitors in CLL

June 15th 2021

Parameswaran Venugopal, MD, discussed the toxicity profiles of BTK inhibitors regarding treatment selection in CLL.

Frontline Ibrutinib/Venetoclax Yields Superior Outcomes Vs Chlorambucil/Obinutuzumab in CLL

June 12th 2021

Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior progression-free survival compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia.

Dr. Ghia on the Efficacy of Ibrutinib/Venetoclax in CLL

June 12th 2021

Paolo Ghia, MD, PhD, discusses results seen with the combination of ibrutinib and venetoclax as a first-line treatment for patients with chronic lymphocytic leukemia.

Hillmen Highlights Acalabrutinib’s Tolerability Vs Ibrutinib in Previously Treated CLL

June 12th 2021

The next-generation, selective BTK inhibitor acalabrutinib demonstrated noninferiority to ibrutinib in terms of progression-free survival in patients with previously treated chronic lymphocytic leukemia in the phase 3 ELEVATE-RR trial.

Dr. Epperla on the Implications of an FDA Approval for Ublituximab/Umbralisib in CLL

June 12th 2021

Narendranath Epperla, MD, MS, discusses the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia.

Zanubrutinib Demonstrates Impressive Responses in Relapsed/Refractory CLL

June 11th 2021

Zanubrutinib continued to induce deep responses with acceptable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia, including those with high-risk cytogenetics.

Dr. Barr on the Next Steps of the RESONATE-2 Trial in CLL

June 11th 2021

Paul M. Barr, MD, discusses the next steps of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Hillmen on Results With Acalabrutinib in CLL

June 11th 2021

Peter Hillmen, MD, PhD, discusses results reported with acalabrutinib in patients with chronic lymphocytic leukemia, as demonstrated in a phase 3 trial.

Fixed-Dose Venetoclax/Obinutuzumab Combo Maintains PFS Benefit at 3 Years Following Treatment Cessation

June 11th 2021

The fixed-dose combination of the BCL-2 inhibitor venetoclax and the humanized anti-CD20 monoclonal antibody obinutuzumab continued to confer a progression-free survival advantage over chlorambucil plus obinutuzumab for patients with previously untreated chronic lymphocytic leukemia.

Dr. Al-Sawaf on the Efficacy of Venetoclax/Obinutuzumab in Treatment-Naïve CLL

June 11th 2021

Othman Al-Sawaf, MD, discusses the efficacy of venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia, as demonstrated in the phase 3 CLL14 trial.

Zanubrutinib May Be Superior to Ibrutinib in Relapsed/Refractory CLL/SLL

June 11th 2021

Zanubrutinib induced superior response and progression-free survival rates, as well as lower rates of atrial fibrillation/flutter than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.